Kiniksa Pharmaceuticals, Ltd.
Stable Anti-OSMR Antibody Formulation
Last updated:
Abstract:
The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.
Status:
Application
Type:
Utility
Filling date:
8 Sep 2021
Issue date:
3 Mar 2022